CeQur


PaQ is not cleared for use in the United States

Introduction to PaQ®

PaQ is a three day insulin delivery device developed specifically for people with type 2 diabetes. The device is small and discreet proving both constant basal (background) insulin and bolus (mealtime) insulin. PaQ enables a life free from the burden of daily insulin injections.

PaQ has two components:


Infuser Unit

  • Continuous basal insulin
  • Push button bolus insulin
  • 3 day use

Messenger Unit

  • Notification when to replace device and time of use
  • 1 year use

How to Use PaQ®



PaQ® Facts

  • Developed specifically for people with type 2 diabetes
  • Up to 3 days of continuous subcutaneous insulin delivery
  • Worn on the abdomen
    • Small, ergonomic design
    • Be active, sleep, eat, exercise
    • Bathe, shower, swim (depth up to 6 ft)
  • Utilizes U100 rapid-acting insulin

  • 7 preset basal doses
  • 2 bolus units delivered with each button push
  • Delivers up to 330 units over 3 days

PaQ® Clinical Results

A recently completed clinical study evaluated the ability of people with Type 2 diabetes to use simple insulin infusion with the PaQ insulin delivery device to replace multiple daily injections. Study endpoints included glycemic control, patient satisfaction and safety. The only change from the baseline period of multiple daily injections and PaQ treatment was using the device to deliver insulin. Click here to view the study.

PaQ is Simple to Train, Use and Transition
  • With only one hour of training all participants were able to easily assemble and use PaQ without user errors.
  • All study participants were "very satisfied" (83%) or "satisfied" (17%) with the time it took to learn how to use PaQ and to administer bolus doses with PaQ
  • Transition was done simply and safely with 75% of the trial participants transitioning to PaQ with the first basal rate selected.
PaQ Effectively and Safely Delivers Basal and Bolus Insulin
  • Total daily insulin dose was similar on PaQ to baseline MDI therapy
    • Half the participants were able to reduce their insulin usage by more than 10% while on PaQ
  • PaQ was well tolerated
  • Hypoglycemia throughout the study was comparable to MDI, with fewer participants having hypo during the PaQ treatment period
  • Additional data being released at the ADA 73rd Scientific Sessions being held in Chicago.
PaQ Delivers Freedom From Daily Injections
  • Study participants found the device to be less embarrassing, less of a burden and less painful than current insulin injection treatments.
  • Additional data being released at American Diabetes Association 73rd Scientific Sessions.

Publications

PaQ®, a Simple 3-Day Basal/Bolus Insulin Delivery Device, in Patients with Type 2 Diabetes

Abstract published at Advanced Technologies & Treatments for Diabetes 6th International Conference

A Feasibility Assessment of PaQ®, a Simple 3-Day Basal/Bolus Insulin Delivery Device, in Patients with Type 2 Diabetes

Poster to be published at American Diabetes Association 73rd Scientific Sessions

Use of PaQ®, a Simple 3-Day Basal/Bolus Insulin Delivery Device, Reduces Barriers to Insulin Therapy in Patients with Type 2 Diabetes

Poster to be published at American Diabetes Association 73rd Scientific Sessions